Safety study of a new immune therapy for neuromyelitis optica
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have a confirmed diagnosis of NMOSD and test positive for the AQP4 antibody.
- You should have had no NMOSD relapses in the last 12 months.
- You need to be on a stable dose of ravulizumab or satralizumab for at least 6 months.
- You must have up-to-date meningococcal vaccines and join any required safety program.
- You should have certain blood counts within normal limits and no serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
Hear when a new AQP4+ NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.